We reviewed the MEDLINE database of art icles published fro m Janu ary 1966 through December 2001 in search of data on the abili ty of the corticos teroid dexam etha sone to protect against senso rineural hearin g loss in children with meningitis. We f ound 1,034 art icles that matched our keyword entries, and aftervarious excl usions, we winnowed this number down to 16 articles that contained adequate data regarding audiometric evaluation andfo llow -up. The 16 articles included reports of 11 rando mized controlled trials (only 10 are considered in this analysis), two metaanalyses, two retrospective case series, and two consensus statements, Of the 10 clinica l trials (all ofwhich conta ined level 1 evidence), four showed that dexa me thaso ne had a p rotective effect and six showed that it did not. The autho rs ofthe two meta-analyses (both level 1) concluded that there was a protective effect, and the autho rs ofthe two retrospective case series (both level1V) concl uded that there was not. Both consensus statements (bo th level V)recommended the use ofdexam etha sone only in Haemop hilus influenzae meningitis. We conclude that well-designedstudies with level 1evidence hav e shown that the benefit of dexam ethasone in preventin g hearing loss in children with menin gitis remains unclew: Signifi cant variables in treatm ent response incl ude the specijic patho gen, the type ofantibiotic, and the timin g ofdexamethasone administration.
Introduction
Bacterial menin git is affec ts approximately 15,000 infant s and children in the United States eac h year. 1Despit e the ava ilabi lity of potent antimicrobial age nts, 1.5 to 5% of ch ildren with bacterial men ingit is die; amo ng the survivors, 15 to 20 % have sig nifica nt long-term neurolog ic sequelae, such as ep ilepsy, motor dysfun ct ion, and rerardano n.>' Th ese sequelae are more co mmo n in patients who have more severe disease at present ation, as is frequ ently seen in developin g countries.i" By far, the most com mon long-term effect of bacterial meningitis in children is sensorineural hearing loss (SNHL), which is ofte n severe or profound and bilater aJ. 2·9 . 1O The reported incidence of SNHL ranges fro m 5% to more than 20%, depending on the type of audio logic surveillance.II Dur ing the past 2 decades, several exce llent randomized trials have been co nducted to investigate the effectiveness of the corticos tero id dexamethasone in preventi ng the sequelae of bacterial meningitis in infa nts and child ren.12·21 However, result s have been conflicting.F" The aim of our review was to eva luate the quality of the evidence in these studies in the hope of arriving at a definitive conclusion about the ability of dexamethasone to protect against SNHL in children with bacterial meningitis.
Materials and methods
We searched the ME DLINE database of articles published from January 1966 through Decemb er 200 1 using the MESH term s meni ngitis, hearing loss, and dexam ethasone. The search iden tified 1,034 articles that matched the keyword entries. Of these, 170 articles were rele vant to the protective effect of dexameth asone in bacteri al meningitis. The abstrac ts of these articles were reviewe d by 5 individuals: 3 senior otolary ngology faculty members, I pediatric otolaryngo logy fellow, and 1senior resident. The reviewe rs catego rized each report acco rding to the 5-point grading system for data class deve loped by the Oxford Centr e for Evidence-Based Medici ne. After excluding reviews, case reports, non-English-language publi cations, editorial comme nts, etc., we were left with 65 articles that addressed the issue of dexamethaso ne and meningitis. Of these, 16 contained adequate data regarding audiometric evaluatio n and follow-up, and these articles served as the foundation of this evi dence -base d analysis .
Results
The 16 articles incl uded I I rando mize d controlled trials (only 10 of which are included in this analysis),'>" two meta-analyses.P:" two retrospective case series, 24 RCT compared adjunctive dexamethasone with placebo in reducing the risk of SNHL in bacterial meningitis in children. Dexamethasone was given 20 minutes prior to parenteral antibiotics at a dose of 0.6 mg/kg/day for 4 doses. N=50
RCT compared dexamethasone's effects on hearing loss and neurologic and developmental outcomes in children with bacterial meningitis. Dexamethasone was given prior to parenteral antibiot ics at 0.6 mg/kg/day in four doses . N=89
RCT measured the effects of dexamethasone and glycerol in the treatment of bacterial meningitis in infants and children. N = 122 RCT compared dexamethasone with placebo in children older than 2 years who had pneumococcal mening itis. Dexamethasone was given 20 minutes prior to parenteral antibiotics at 0.6 mgt kg/day in four doses. N=60
Multicenter RCT was conducted to assess the efficacy of dexamethasone as an adjunctive therapy for bacterial meningitis in children. Dexamethasone was given at a dose of 0.15 mg/kg/day for 4 days within 4 hours of the antibiotic dose . N = 173
RCT examined the use of dexamethasone in children with bacterial meningitis . Dexamethasone was given 10 minutes prior to a parenteral antibiotic at a dose of 0.4 mg/kg/day for 2 days. N = 115
Evidence level Summary
The dexamethasone group had 2 infants with SNHL, compared with 1 in the control group (7.4 vs. 4%). The difference was not stat istically significant. No power analysis was performed.
Fewer patients in the dexamethasone group developed mild and severe persistent hearing loss (19 vs. 38%). No power analysis was performed. No p values for cumulative hearing loss data were reported.
Authors found no statistically significant difference in outcomes between the dexamethasone group and the placebo controls with respect to hearing loss at 1 and 12 months postinfection. Authors used multivariate analysis to control for factors other than dexamethasone use, includ ing duration of illness prior to admission.
Some 10% of study part icipants developed SNHL. Hearing loss was more common in patients who were not given dexamethasone, although the difference did not reach statisical significan ce (p = 0.14) . No power analysis was performed.
The incidence of both unilateral and bilateral SNHL was lower in the dexamethasone-treated group, but the difference was not stat istically significant (7.4 vs. 23%; p = 0.11). No power analysis was performed .
Overall, no difference in audiometric outcomes between the dexamethasone group and the placebo controls was observed. However, patients with Hibinduced meningit is who were treated with dexamethasone had a significantly lower rate of SNHL (p = 0.02) .
Authors found a higher incidence of SNHL in the placebo group, but the difference did not reach stat istical significance (5 vs. 15 % ; P = 0.11) . No power analysis was performed. Kennedy et al, 25 1991 Description RCT assessed the effects of adjuvant dexamethasone in bact erial meningit is in children. The steroid was given 15 to 20 minutes prior to a parenteral antibiotic for 4 days at a dose of 0.6 mg/ kg/day. N= 10 1
RCT assessed ampicillin and chloramphenicol w ith and without dexamethasone given on a nonselective alternating basis to children and adults (8 mg for patients young er than 12 years and 12 mg for tho se older) for 3 days. The ste roid was given concomitantly with the antibiotics.
N= 429
Two RCTs compared the efficacy of an antibiotic with and without adjunctive dexamethasone in the treatment of bacterial meningitis in children.
Dexamethasone was given at a dose of 0.15 mg/ kg/d ay for 4 days.
N = 200
Meta-analysis includ ed 11 RCTs publish ed from January 1988 through November 1996 on the use of dexamethasone as an adjunctive therapy for bacterial meningiti s.
Met a-analysis evaluated 5 RCTs in children and 1 study with children and adults to evaluate the effec t of dexamethasone as an adjunctive therap y for the treatment of bacterial mening itis. Studi es were published between 1989 and 1991.
Retrospective case series looked at children with pneumoco ccal meningiti s. Some 40 children (22%) were treated with dexamethasone. N = 180
Retrospect ive case series reviewed patients admitte d and treated for pneumoco ccal meningitis and given steroids. Some patients were part of clinical trials of dexamethasone therapy. N =97
Evidence level
IV IV Summary SNHL was more common in the placebo co ntrols, but the difference did not reach statistical significance (6 vs. 16% ; p = 0.18 ). No powe r analysis was performed.
The incid ence of SNHL was lower among those who received dexamethasone, but the advantage was statistica lly significant only in patients who had Streptococcu s pneumoniae infec tions (p = 0.05) .
Ch ildren who received dexamethasone we re significa ntly less likely to experience SNHL than were placeb o contro ls (3 vs.
S econd arm of this study.
Dexamethasone provided prot ection against SNHL in patients with Hib meningitis and pneumoco ccal infection when given prior to parenteral antibiotics.
Placebo controls had a higher relative risk of bilateral SNHL and the need fo r hearing aids (relative risks: 4.12 and 20.94 , respect ively). The diff erence between groups in unilateral hearing loss was not statistically significant (relative risk: 1.09).
The incidence of SNHL was higher in dexamethasone patients than in placebo co ntrols (46 vs. 23%). However, the autho rs noted a trend toward giving the steroid to sicker children; when this trend was taken into acco unt, the difference in SNHL was no longer statistically significant.
Mod erate or wo rse bilateral hearing loss was less common in the ste roid-treated pat ients, but not significantly so (p = 0.13). co ntai ned in all the clinical trials and both me ta-analyses was rated as level 1.The 2 case series were rated level IV, and the two consensus statements were rated level V.
Of the level I reports, fo ur ra ndo mize d co ntro lle d tri-als13.17,20.21and both meta-a nalyses showed thatdexam ethasone did confer some beneficial effec t in preventing SNHL, and six rand omi zed cont roll ed trials I2. 14.16 ,1 8.19showed tha t it did not (table I) .
The Seiler202 ENT Office Examining Microscope starts well under$5,000.
Paying too much for an office examining microscope is now a "t hlnq of the past"! The authors oft he two retrospective case series concluded that dexamethasone conferred no protective benefit.i' :" Both consensus statements recommend the use of dexametha sone only in patients with Haemophilus infiuenzae menin giti s.1. 26 We co nclude, therefore, that the benefit of dexameth asone in preventing SNHL in children with meningitis rem ains unclear, despite the publ ication of well-desi gned studies with level I evidence. Significant variables affecting treatment response include the specific path ogen, the type of antibiotic, and the timing of dexameth asone admini stration.
Discussion
Two strategies have evolved to reduce the disease burden in patients with bacterial menin gitis: ( I) active immuni zation against the most common patho gens and (2) reduction of central nervous system inflammati on with anti-inflammatory therapy.18Immuni zation is highly effective, and it has already significantly reduced the number of meningitis cases caused by H infi uenzae. 27 -29 Steroids are the only anti-inflammatory agents that have been extensi vely studied in clinical trials for the prevention of neurologic complications of meningitis, includin g SNHL. Th ere is good evidence that the inflammatory cascade induced by bacterial produ cts during bacteri al lysis is initiated and maintained by cytokines-tumor necrosis factor alpha (TNF-a) and interleukin-l-beta (lL-l~) in particular.P '" Stud ies in rabbits have shown that pretreatment with a steroid prior to intrathecal injection with H infiuenzae results in a redu ction in conc ent rations ofTNF-a and IL_I~. 33 -3 5 Similar findings have been seen in anim al models of pneumococcal meningiti s.v -"
The modern era of steroid use in bacterial meningiti s trials began in Dalla s with a repo rt of two double-blind, randomized trials by Lebel et al in 1988. 21 The first trial showed that patient s who receiv ed adj unctive dexamethasone had a significantly lower rate of SNHL than did patient s who receive d antibiotic alone. However, the antibiotic used in the first trial was cefuroxime, an agent that is not often used because it require s a relatively long time to sterilize the cerebrospinal fluid (CSF). 38.39 Additionall y, most of the patients in that trial (77%) had H infiuenzae type b menin giti s, which is belie ved to be more respon sive to dexamethasone. Therefore, we did not include the result s of that first study in this analysis. In the second arm of this study, which is included in this analysis, the authors used ceftriaxone, which is a much more effective agent and rapidl y sterilizes CSF. Dexamethasone was found to be protective in this study, as well.
The reaso ns for the lack of definitive findings in these level I trials can be attributed to three variables: ( I) the specific pathogen, (2) the type of antibiotic administered, and (3) the timing of dexamethasone admini stration.
Pathogen. The three most comm on causative bacteria Volume 85, Number 9 are H infiuenzae , Strepto cocc us pn eum oniae, and Neisseria menin gitidis. Dexameth asone was most prote ctive in patient s who had H infiuenzae meningitis. Tho se who had S pneumonia e or N menin gitidis menin gitis either did not respond to the steroid or their numb ers were too small to allow for a meaningful conclusion.1. [24] [25] [26] Type of antibiotic. Ceftria xone is more effective than both cefo taxime and cefuroxi me in treating meningitis.w" Studies in which cefotaxime and cefuroxime were used are potentially biased because these drugs enhance the protective effect of steroids.These two cephalosporins take a longer time to sterilize CSF in menin gitis, and therefore the period of inflammation is extended.v -" There are no conclusive data on CSF sterilization with ampicillin plus chloramphenicol or with other antib iotics that have been studied .
Timing of the steroid dosage. In the four studies that showe d that dexameth asone had a protective effect against SNHL , the steroid was administered either before the antibiotic.P?' concurrently with the antibiotic," or within 4 hours of antibiotic administration. 17 A powe r analysis was not perform ed in any of the clinical trials. The only such analy sis was conducted by Geim an and Smith in their meta-analysis." Their power analysis showed that bilateral SNHL occurred with greater frequency in patient s who did not recei ve a steroid. This was significant in view of the numbe r of patients who were includ ed in the analysis. However, one of the studies in this meta-analysis included adults.
In the meta-analysis by McIntyree t al, the authors reached a similar conclu sion without a power analysis." However, the beneficial effect of dexamethasone was seen only in patients who had H influenzae b infection .Also, in pati ents with S pn eum onia e meningitis, the met a-analysis found that dexameth asone had a protective effect only when it was administered prior to antibiotic administration.
No statistically significant incidence of steroid-related side effects in the treatment of meningiti s has been repor ted. 23 . 25 The durati on of steroid treatment does not influence its protective effect, as shown by Syrogiannopoulos et al in a comp arison of 2and 4-day regimens.f Audiometric follo w-up in the 16 studies varied widely, and the stability of SNHL was not examined . However, experience gained during two other studi es indicates that SNHL after meningitis can be progres sive in patients with H influenzae and Spneumoniae infections. 43.44 Anaddition al consideration is ossification of the lab yrinth in child ren with SNHL after meningitis; in a retrospecti ve study (leve l IV) reported by Hartnick et al in 200 I , dexamethaso ne was show n to have a protecti ve effec t against cochlear ossification after meningitis."
In conclusion, the current literature suggests that there is grade B evidence in favor of the use of dexameth asone in patient s with H infillenzae-associated meningitis and grade C evidence for its use in patient s with other bacteria.
(A grade of B indica tes consis tent results in level II or III studies or extrapolations from level I studies; a grade of C indicates da ta from level IV studies or extrapolations from level II or III studies.)
